ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis.
Michael Situ et al.PubMed ↗Publisher ↗
No numbers read from the abstract.